Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: NDAC meetings

This article was originally published in The Tan Sheet

Executive Summary

NDAC meetings: Tentative joint meeting of FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs Advisory Committees scheduled for July 16; topics are still in development. Both committees also are scheduled to meet July 14 and 15. NDAC will meet jointly with the Pulmonary-Allergy Drugs Advisory Committee Sept. 18-19, possibly for reconsideration of the Rx-to-OTC switch of Schering-Plough's Vancenase AQ. Review of the beclomethasone dipropionate nasal spray was postponed last September at the company's request ("The Tan Sheet" Sept. 30, 1996, p. 9). Schering asked for the delay to further analyze its data before presenting before the committee...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086996

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel